Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-03
2006-10-03
Owens, Amelia A. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07115606
ABSTRACT:
The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HT3antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.
REFERENCES:
patent: 4695568 (1987-09-01), Ninomiya et al.
patent: 4939136 (1990-07-01), Haeck et al.
patent: 5225407 (1993-07-01), Oakley et al.
patent: 5352685 (1994-10-01), Maruyama et al.
patent: 5663343 (1997-09-01), van der Meij et al.
patent: 5945415 (1999-08-01), Kato et al.
patent: 5962494 (1999-10-01), Young
patent: 5977127 (1999-11-01), Bonnacker et al.
patent: 6300336 (2001-10-01), Eeckhout et al.
patent: 6355647 (2002-03-01), Steiner et al.
patent: 6440453 (2002-08-01), Fischer et al.
patent: 6465458 (2002-10-01), Wong et al.
patent: 6846823 (2005-01-01), Landau et al.
patent: 2001/0020025 (2001-09-01), Megens
patent: 2002/0002167 (2002-01-01), Mueller et al.
patent: 2002/0010216 (2002-01-01), Rogosky et al.
patent: 2002/0107249 (2002-08-01), Wong et al.
patent: 2003/0158221 (2003-08-01), Zhang et al.
patent: 2003/0203055 (2003-10-01), Rao et al.
patent: 2004/0048874 (2004-03-01), Bardsley et al.
patent: 0216027.3 (2002-07-01), None
patent: 0220064.0 (2002-08-01), None
patent: 0304648.9 (2003-02-01), None
patent: 0316115.5 (2003-09-01), None
patent: 06016557 (1994-01-01), None
patent: WO 98/50037 (1998-11-01), None
patent: WO 00/06160 (2000-02-01), None
patent: WO 00/48581 (2000-08-01), None
patent: WO 01/26623 (2001-04-01), None
patent: WO 02/094249 (2002-11-01), None
patent: WO 03/061657 (2003-07-01), None
patent: WO 03/063873 (2003-08-01), None
patent: WO 03/077897 (2003-09-01), None
patent: WO 2004/004734 (2004-01-01), None
patent: WO 2004/019948 (2004-03-01), None
Clemett, Tolterodine: a review of its use in the treatment of overactive bladder, PMID: 11341475 (2001).
Hofner, Trospium chloride—an effective drug in the treatment of overactive bladder and detrusor hyperreflexia, World J Urol (2001) 19:336-343.
Hunsballe, Clinical options for imipramine in the management of urinary incontinence, Urol Res (2001) 29:118-125.
U.S. Appl. No. 10/757,981, filed Jan. 13, 2004, Landau et al.
Andersson, K. E., “Treatment of Overactive Bladder: Other Drug Mechanisms,” Urology, 55(Supplement 5A):51-59 (2000).
Andersson, K.E., “Treatment of the Overactive Bladder: Possible Central Nervous System Drug Targets,” Urology, 59 (Suppl 5A):18.
Andersson, K.E., “Bladder Activation: Afferent Mechanisms,” Urology, 59 (Suppl 5A):43.
Appell, R. A. et al., “Prospective Randomized Controlled Trial of Extended-Release Oxybutynin Chloride and Tolterodine Tartrate in the Treatment of Overactive Bladder: Results of the OBJECT Study,” Mayo Clin. Proc. 76:358-363 (2001).
Barras, M. et al., “Characterisation of the 5-HT Receptor Potentiating Neurotransmission in Rabbit Bladder,” Eur. J. Pharmacol., 318(2-3):425-428 (1996).
Béïque, J.-C. et al., “Affinities of Venlafaxine and Various Reuptake Inhibitors for the Serotonin and Norepinephrine Transporters,” Eur. J. Pharmacol., 349:129-132 (1998).
Burns, M. J., The Pharmacology and Toxicology of Reboxetine, [Retrieved from the Internet Dec. 4, 2002]. Retrieved from the Internet <http://www.ijmt.net/3—4/3—4—26.html>.
Butler, A. et al., “Pharmacological Properties of GR38032F, a Novel Antagonist at 5-HT3 Receptors,” Br. J. Pharmacol., 94(2): 397-412 (1988).
Bymaster, F. P. et al., “Comparative Affinity of Duloxetine and Venlafaxine for Serotonin Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors,” Neuropharmacol., 25(6):871-880 (2001).
Center for Drug Evaluation and Research Application No.: 020623; Pharmacology Reviews; Jul. 5, 1996.
Chancellor, M.B., “New Frontiers in the Treatment of Overactive Bladder and Incontinence,” Reviews in Urology, 4(4): S50-S56 (2002).
Chuang, Y.C. et al., “Intravesical Protamine Sulfate and Potassium Chloride as a Model for Bladder Hyperactivity,” Urology, 61(3): 664.
Collins M.M. et al., “How Common is Prostatitis? A National Survey of Physician Visits,” J. Urol., 159:1224-1228 (1998).
Downie, J.W., “Pharmacological Manipulation of Central Micturition Circuitry,” Curr. Opin. CPNS Inves. Drugs, 1(2):231.
Eguchi, J. et al., “Pharmacological Profile of the Novel Antidepressant 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno-[2,3-d]pyrimidine Monohydrate Hydrochloride,” Arzneim.-Forschung/Drug Res., 47(12):1337-47 (1997).
Eguchi, J. et al., “The Anxiolytic-like Effect of MCI-225, a Selective NA Reuptake Inhibitor with 5-HT3 Receptor Antagonism,” Pharm., Biochem. and Behavior 68:677-683 (2001).
Elliott, D. S. et al., “Medical Management of Overactive Bladder,” Mayo Clin. Proc. 76:353-355 (2001).
Elmiron® (pentosan polysulfate sodium), capsules, Product Information, Ortho-McNeil Pharmaceutical,Inc., Ranitan, N.J. (2002).
Espey, M.J. et al., “Serotonergic Modulation of Spinal Ascending Activity and Sacral Reflex Activity Evoked by Pelvic Nerve Stimulation in Cats,” Brain Res., 798(1-2):101-108 (1998).
Evans, R.J., “Treatment Approaches for Interstitial Cystitis: Multimodality Therapy,” Reviews in Urology, 4(Suppl. 1): S16-S20 (2002).
Fairweather, D. B. et al., “The Psychomotor and Cognitive Effects of Litoxetine in Young and Middle Aged Volunteers,” Br. J. Clin. Pharmacol. 40:119-125 (1995).
Ito, C. et al., “Effect of GK-128 [2-[(2-Methylimidazol-1-yl)methyl]-benzo[f]thiochromen-1-one Monohydrocholoride Hemihydrate], a Selective 5-Hydroxytryptamine3 Receptor Antagonist, on Colonic Function in Rats,” J. Pharmacol. Exp. Ther., 280(1): 67-72 (1997).
Katofiasc, M. A. et al., “Comparison of the Effects of Serotonin Selective, Norepinephrine Selective, and Dual Serotonin and Norepinephrine Reuptake Inhibitors on Lower Urinary Tract Function in Cats,” Life Sci., 71:1227-1236 (2002).
Khan, M.A. et al., “Doxazosin Modifies Serotonin-Mediated Rabbit Urinary Bladder Contraction. Potential Clinical Relevance,” Urol. Res., 28:116-121 (2000).
Kilpatrick, G.J. et al., “Identification and Distribution of 5-HT3 Receptors in Rat Brain Using Radioligand Binding,” Nature, 330: 746-748 (1987).
Kodama, M. and Takimoto, Y., “Influence of 5-Hydroxytryptamine and the Effect of a New Serotonin Receptor Antagonist (Sarpogrelate) on Detrusor Smooth Muscle of Streptozotocin-Induced Diabetes Mellitus in the Rat,” International Journal of Urology 7:231-235 (2000).
LOTRONEX (alosetron hydrochloride)—Tablets, Product Information, GlaxoSmithKline, Research Triangle Park, NC, pp. 1-13 (2002).
Metts, J. F., “Interstitial Cystitis: Urgency and Frequency Syndrome,” American Family Physician, 64(7): 1199.
Morrison, J. et al., “Neurophysiology and Neuropharmacology” In: Incontinence (vol. 2) Abrams, P., Cardozo, L., Khoury, S., and Wein, A., Eds. (UK, Health Publications, Ltd.,) pp. 83.
Owens, M. J. et al., “Neurotransmitter Receptor and Transporter Binding Profile o
Fraser Matthew O.
Landau Steven B.
Miller Cheryl L.
Dynogen Pharmaceuticals, Inc.
Jones Day
Owens Amelia A.
LandOfFree
Method of treating lower urinary tract disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating lower urinary tract disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating lower urinary tract disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3655016